	FORM	4	UNITED) STA	TES						NGE	CO	MMIS	SION				
		Washington, D.C. 20549												OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				EMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										₹SHIP		Numbe ated av per res	erage burden	3235-0287 0.5
1. Name and Address of Reporting Person* Doshi Dipal (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol <u>Entrada Therapeutics, Inc.</u> [TRDA] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022									ck all applica Director Officer (below)	able) give title	10% Owner		ner
C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET															residen	t und		
(Street) BOSTON MA 02210			02210		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. In Line									 ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(S	tate)	(Zip)											Feison				
		Та	ble I - Non	n-Deriv	ative	Securitie	s Ac	quired,	Dis	posed o	of, or E	Bene	ficially	Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month/I					Executio	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			4 and 5) Securities Beneficia Owned Fo		Form (D) or	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									v	Amount (A) or (D)		Price	Reported Transacti (Instr. 3 a	on(s) nd 4)			Instr. 4)	
Common Stock 03/01				/2022		Α		30,25	250 ⁽¹⁾ A		\$0 ⁽¹⁾	214,710 ⁽²⁾			D			
			Table II - I (ecurities alls, war								Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansactio ode (Insi	n Derivati r. Securiti Acquire or Dispo of (D) (II	Derivative E		6. Date Exercisable : Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s dly g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Co	ode V	(A)	(D)	Date Exercisab		xpiration	Title	or N	mount umber f Shares	int (li ber		ion(s)		
Stock Option (Right to Buy)	\$11.57	03/01/2022		1	4	181,500		(3)	0	3/01/2032	Commo stock		81,500	\$ <mark>0</mark>	181,5	00	D	

Explanation of Responses:

SEC Form 4

1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

2. Consists of (i) 172,467 shares of common stock (ii) 11,993 shares of restricted common stock issued upon early exercise of stock options, and (iii) 30,250 RSUs reported in this transaction.

3. 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

<u>/s/ Jared Cohen, as Attorney-in-</u>	03/03/2022
<u>Fact</u>	03/03/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.